Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

NCT06838208 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Tislelizumab, Carboplatin /Cisplatin, Etoposide

Sponsor

Anhui Provincial Cancer Hospital